Novartis digs into safety data in Avastin-vs.-Lucentis study

Novartis ($NVS) couldn't let the Avastin-vs.-Lucentis study pass by without comment. Two-year data from that head-to-head trial, funded by the National Eye Institute, showed that the two drugs were ev…
Read the full story: News